Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia

[News]

Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled "Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer."

More... (http://www.news-medical.net/news/20120723/Berg-Pharma-initiates-BPM-31543-clinical-trial-for-chemotherapy-induced-alopecia.aspx)